
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 24, 2017

GEOVAX LABS, INC.

(Exact name of registrant as specified in Charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

000-52091
(Commission File No.)

87-0455038
(IRS Employee Identification No.)

1900 Lake Park Drive
Suite 380
Smyrna, Georgia 30080
(Address of Principal Executive Offices)

(678) 384-7220
(Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below).

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13(e)-4(c))

This Form 8-K and other reports filed by GeoVax Labs, Inc. (the “registrant”) from time to time with the Securities and Exchange Commission (collectively the “Filings”) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management. When used in the Filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of these terms and similar expressions as they relate to the registrant or the registrant's management identify forward looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Item 2.02 Results of Operations and Financial Condition

On March 24, 2017 we issued a press release reporting our results of operations for the year ended December 31, 2016. A copy of the press release is attached to this Current Report.

Item 9.01 Financial Statements and Exhibits

Exhibit 99.1 Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 24, 2017

GEOVAX LABS, INC.

By: /s/ Mark W. Reynolds
Mark W. Reynolds
Chief Financial Officer



GeoVax Reports 2016 Year-End Financial Results

ATLANTA, GA, March 24, 2017 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2016.

GeoVax reported a net loss for the year ended December 31, 2016 of \$3.3 million, or \$0.08 per share, based on 41.5 million weighted average shares outstanding. For the year ended December 31, 2015, the Company reported a loss of \$2.7 million, or \$0.08 per share, based on 32.0 million weighted average shares outstanding.

The Company reported revenues of \$0.8 million for 2016, related to grants from the NIH, as compared to \$0.4 million in 2015. Research and development (R&D) expenses were \$2.0 million in 2016, compared with \$1.7 million in 2015. General and administrative (G&A) expenses were \$2.1 million in 2016, compared to \$1.4 million in 2015. Cash balances were \$0.5 million at December 31, 2016, compared to \$1.1 million at December 31, 2015.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission.

About GeoVax

GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) vaccine platform. The Company's development programs are focused on preventive vaccines against HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. GeoVax's vaccine platform supports *in vivo* production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.

Contact:

Robert T. McNally, Ph.D.
GeoVax Labs, Inc.
investor@geovax.com
678-384-7220

FINANCIAL TABLES FOLLOW

MORE

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except per share data)

	Year Ended December 31,	
	2016	2015
Grant Revenue	\$ 828	\$ 428
Operating expenses:		
Research and development	1,971	1,693
General and administrative	2,131	1,429
	4,102	3,122
Loss from operations	(3,274)	(2,694)
Interest income	2	5
Net loss	\$ (3,272)	\$ (2,689)
Net loss per common share	\$ (0.08)	\$ (0.08)
Weighted average shares outstanding	41,517	31,951

Condensed Consolidated Balance Sheet Information
(amounts in thousands)

	December 31,	
	2016	2015
Assets:		
Cash and cash equivalents	\$ 454	\$ 1,060
Other current assets	90	177
Total current assets	544	1,237
Property, net	55	84
Other assets	11	11
Total assets	\$ 610	\$ 1,332
Liabilities and stockholders' equity		
Current liabilities	\$ 370	\$ 127
Stockholders' equity	240	1,205
Total liabilities and stockholders' equity	\$ 610	\$ 1,332
Shares Outstanding	55,235	31,951